Project Grant HT94252410106
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
This Project Grant award of $798,272.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research at The Johns Hopkins University to test the use of Wnt inhibitors as a potential therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The research project will be conducted over a 2-year period from March 2025 to March 2027, with the goal of advancing...
The Department of the Army Medical Command awarded The Johns Hopkins University a $982,500 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting M6A Dysregulation as a Novel Therapeutic Strategy for C9ORF72-ALS". The award period is May 1, 2024 to April 30, 2026. This research aims to develop new treatments for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with a focus on the C9ORF72 genetic...
The Johns Hopkins University received a $2,455,671.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an AAV-based gene therapy for amyotrophic lateral sclerosis (ALS). The award, effective June 1, 2024 through May 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research and advance therapeutic solutions for this neurological disorder. The federal grant funding supports the university's...
The Department of the Army Medical Command awarded a $931,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Johns Hopkins University to develop a RIPK2 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). The award period runs from July 1, 2025 to June 30, 2027. As a leading academic research institution, The Johns Hopkins University has a strong track record of conducting advanced biomedical research and delivering innovative...
The Johns Hopkins University was awarded an $818,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support research into RNA-based modulation of TDP-43 mislocalization in ALS/FTD with uridine analogs from September 15, 2022 to September 14, 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The federal Project Grant award, valued at $962,713.00 and awarded on June 15, 2025 by the Defense Health Agency, supports research to develop robust subtype markers for patient stratification in amyotrophic lateral sclerosis (ALS) under the Military Medical Research and Development (CFDA 12.420) program. The research, conducted by Arizona State University, aims to transform healthcare for military service members and the broader public by advancing disease prevention, diagnosis, treatment,...
This federal Project Grant award of $1,078,882.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research focused on developing innovative therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the multimodal therapeutic actions of donor and host neural stem cells. Key research services include consultation on surgical intervention methods for delivering compounds...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...